Vontobel Holding’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $517K | Sell |
4,111
-5,832
| -59% | -$733K | ﹤0.01% | 779 |
|
|
2025
Q1 | $1.1M | Buy |
9,943
+1,501
| +18% | +$166K | ﹤0.01% | 566 |
|
|
2024
Q4 | $1.15M | Sell |
8,442
-6,148
| -42% | -$839K | ﹤0.01% | 558 |
|
|
2024
Q3 | $1.68M | Buy |
14,590
+1,639
| +13% | +$189K | 0.01% | 486 |
|
|
2024
Q2 | $1.78M | Buy |
12,951
+4,801
| +59% | +$661K | 0.01% | 448 |
|
|
2024
Q1 | $1.12M | Buy |
8,150
+2,061
| +34% | +$284K | 0.01% | 552 |
|
|
2023
Q4 | $802K | Sell |
6,089
-2,369
| -28% | -$312K | 0.01% | 659 |
|
|
2023
Q3 | $952K | Sell |
8,458
-1,250
| -13% | -$141K | 0.01% | 596 |
|
|
2023
Q2 | $915K | Sell |
9,708
-595
| -6% | -$56.1K | 0.01% | 620 |
|
|
2023
Q1 | $1.04M | Buy |
10,303
+7,082
| +220% | +$717K | 0.01% | 576 |
|
|
2022
Q4 | $382K | Sell |
3,221
-2,644
| -45% | -$314K | ﹤0.01% | 827 |
|
|
2022
Q3 | $603K | Buy |
5,865
+959
| +20% | +$98.6K | 0.01% | 660 |
|
|
2022
Q2 | $482K | Sell |
4,906
-35,189
| -88% | -$3.46M | 0.01% | 733 |
|
|
2022
Q1 | $3.71M | Buy |
40,095
+18,222
| +83% | +$1.68M | 0.03% | 320 |
|
|
2021
Q4 | $1.85M | Buy |
21,873
+3,890
| +22% | +$329K | 0.02% | 460 |
|
|
2021
Q3 | $1.72M | Sell |
17,983
-1,386
| -7% | -$133K | 0.02% | 476 |
|
|
2021
Q2 | $1.88M | Buy |
19,369
+3,374
| +21% | +$327K | 0.02% | 452 |
|
|
2021
Q1 | $1.56M | Sell |
15,995
-2,858
| -15% | -$278K | 0.01% | 452 |
|
|
2020
Q4 | $2.22M | Buy |
+18,853
| New | +$2.22M | 0.01% | 354 |
|